A propensity score–matched retrospective study found that preoperative bladder artery embolization followed by TURBT within ...

Results from a large study show that adding two drugs, durvalumab and enfortumab vedotin, before bladder cancer surgery ...

A new mini-review outlines how epigenetic silencing of NK-activating ligands helps urothelial carcinoma evade immune attack ...

Zusduri (mitomycin) is a chemotherapy medicine that was approved by the FDA in June 2025 for the treatment of a specific type of bladder cancer known as recurrent low-grade intermediate-risk ...

The study enrolled 25 patients with high-grade bladder cancer that had come back after earlier BCG treatment. Their median ...

On October 14, the U.S. Food and Drug Administration announced that Anktiva (nogapendekin alfa inbakicept-pmln), used together with Bacillus Calmette-Guérin, is now approved for adults with ...

Therapeutic progress has accelerated, with multiple recent approvals improving outcomes across early-stage, muscle-invasive, and metastatic urothelial carcinoma. FGFR3 and HER2 protein expression by ...

En bloc resection is a viable alternative to conventional TURBT, even possibly for large NMIBC and regardless of tumor location. En bloc resection of bladder tumor outperforms transurethral resection ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

Chemotherapy uses medicines to kill fast-growing cells (like cancer cells) or to keep them from dividing (which is how cancers grow). It is a systemic treatment. This means the medicines will travel ...